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Abstract Cytochrome P450-dependent monooxygenases
(CYPs) are involved in the metabolic defence against
xenobiotics. Human CYP3A enzymes metabolise about 50%
of all pharmaceuticals in use today. Induction of CYPs and
associated xenobiotic metabolism occurs also in fish and may
serve as a useful tool for biomonitoring of environmental
contamination. In this study we report on the cloning of a
CYP3A family gene from fathead minnows (Pimephales
promelas), which has been designated as CYP3A126 by the
P450 nomenclature committee (GenBank no. EU332792).
The cDNA was isolated, identified and characterised by
extended inverse polymerase chain reaction (PCR), an alterna-
tive to the commonly used method of rapid amplification of
cDNA ends. In a fathead minnow cell line we identified a full-
length cDNA sequence (1,863 base pairs (bp)) consisting of a
1,536 bp open reading frame encoding a 512 amino acid
protein. Genomic analysis of the identified CYP3A isoenzyme
revealed a DNA sequence consisting of 13 exons and 12
introns. CYP3A126 is also expressed in fathead minnow liver
as demonstrated by reverse transcription PCR. Exposure of
fathead minnow (FHM) cells with the CYP3A inducer
rifampicin leads to dose-dependent increase in putative CYP3A
enzyme activity. In contrast, inhibitory effects of diazepam
treatment were observed on putative CYP3A enzyme activity
and additionally on CYP3A126 mRNA expression. This
indicates that CYP3A is active in FHM cells and that
CYP3A126 is at least in part responsible for this CYP3A
activity. Further investigations will show whether CYP3A126
is involved in the metabolism of environmental chemicals.
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Introduction
Investigations on enzymes involved in the metabolism of
environmental pollutants in fish are important in providing
information about their behaviour and effects in aquatic
organisms. Cytochrome P450-dependent monooxygenases
(CYPs) are involved in the metabolic defence against
xenobiotics. In fish, induction of CYPs and associated
xenobiotic metabolism is well established and may serve as
a useful tool for the biomonitoring of environmental
contaminations [1–4] and in the ecotoxicological assess-
ment of pollutants.
In the last decade, a number of CYP3A genes have been
isolated from several teleost species [5–12]. Up to date the
CYP3A sub-family has much more than 100 sub-family
members (Nelson, Cytochrome P450 web site: http://drnelson.
utmem.edu/CytochromeP450.html). Human CYP3A enzymes
metabolise about 50% of all pharmaceuticals in use today
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[13]. They are also involved in the biosynthesis and
degradation of endogenous compounds such as steroids,
lipids and vitamins. In both mammals and fish the CYP3A
family members are considered to be important drug-
metabolising enzymes. Collectively the CYP3A family
comprises the largest portion of the liver and small intestinal
CYPs [9, 14, 15]. CYP3A induction by typical mammalian
CYP3A inducers rifampicin and dexamethasone was shown
in zebrafish larvae [11] and grass carp in vitro and in vivo
[16]. Exposure of medaka to 17 beta-estradiol suppressed
CYP3A protein production [17]. Similar to mammals
induction of CYP3A expression in fish is probably regulated
by the pregnane X receptor (PXR) [18, 19], but this still needs
to be demonstrated. Exposure of Atlantic salmon to thyroxine
and 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene resulted in
CYP3A and PXR mRNA induction in the liver [20]. A
positive correlation between CYP3A and PXR expression
implies a connection, but this has to be proven. Therefore, a
change in CYP3A expression could indicate an exposure of
an organism to xenobiotics. Furthermore a change in CYP3A
expression could provide information on the metabolism of
the xenobiotics. Catalytic activities of CYP3A have been
determined in different fish by use of different substrates
[16, 21, 22]. It was found that CYP3A enzymatic activity in
fish can easily be determined by application of a modified
human CYP3A activity assay, in which the conversion of a
substrate by CYP3A to a fluorescent product is determined
[14, 15, 22–26].
In our present study, we report on a member of the CYP
3A family in fathead minnow (Pimephales promelas),
identified and characterised in a fathead minnow cell line
(FHM) and verified in adult fathead minnow liver tissue.
Fathead minnow is an important fish species extensively
used in aquatic toxicological research and toxicological
assessment of chemicals. Therefore, identification and
characterisation of its xenobiotic metabolising enzymes
are important. Furthermore, we characterise the FHM cell
line CYP3A enzyme activity after exposure to rifampicin
(a prototypical mammalian CYP3A inducer) and diazepam
(a model mammalian CYP3A substrate) using a CYP3A
activity assay. In addition to the enzyme activity, we
evaluate alterations in CYP3A126 mRNA levels by
quantitative reverse transcription (qRT) PCR after exposure
of FHM cell line to rifampicin and diazepam.
Materials and methods
Chemicals, cell culturing and exposure
Dimethyl sulfoxide (DMSO), acetonitrile (AcN), rifampicin,
7-benzyl-trifluoromethyl coumarin (BFC), and 7-
benzyloxyquinoline (BQ) were purchased from Sigma-
Aldrich, Buchs (Switzerland). Phosphate-buffered saline was
purchased from Roche Diagnostics, Basel (Switzerland).
Diazepam (≥99%) was kindly provided by F. Hoffmann—
La Roche Ltd, Basel (Switzerland).
Stock solutions of rifampicin and diazepam were
prepared in DMSO or acetonitrile (AcN) at a concentration
of 100 mM if not otherwise stated. For the assay, stock
solutions were diluted in cell culture medium resulting in a
maximal solvent concentration of 0.1%. Further concen-
trations were prepared by serial dilution.
FHM P. promelas cells (FHM) were kindly provided by T.
Wahli, University Bern, Switzerland, and grown in DMEM/
F12 (LuBioScience, Lucerne, Switzerland) supplemented
with 5% FBS (Sigma-Aldrich), 20 mM HEPES/pH 7.2
(Sigma-Aldrich) at room temperature (21±2 °C). Cells
were split every 7 days and sub-cultured at a split ratio of
about 1:3.
Huh7 The human hepatoma cell line Huh7 was kindly
provided byM. Heim, University Hospital Basel, Switzerland.
Cells were grown in DMEM with GlutaMAX™ (LuBio-
Science) supplemented with 5%FBS in a humidified incubator
with 5% CO2 at 37 °C. Cells were usually split every 4 days
and sub-cultured at split ratios of about 1: 6.
Exposure to rifampicin and diazepam For exposure experi-
ments, 100,000 cells per well were seeded in 96-well plates
and grown for 24 h in culture medium. After 24 h the
medium was removed, and cells were incubated in phenol
red free medium containing the pharmaceutical (10, 25 and
50 μM of rifampicin or 0.1, 1, 10 and 20 μM of diazepam)
or the solvent control (DMSO for rifampicin and acetoni-
trile for diazepam). The cells were incubated for additional
24 h, and the CYP assay was performed as described
below. For each pharmaceutical, the assay was repeated
three times.
Identification and characterisation of the CYP3A126
IPCR FHM cells were directly lysed in the cell culture flask
and homogenised using a QIA shredder (Qiagen, Switzerland,
cat. no. 79654). Total RNA was extracted using the RNeasy
mini kit (Qiagen, cat. no. 74104; Fig. 1 a). Double-stranded
cDNA (ds cDNA) synthesis was performed using 50 ng/µl
total RNA and the cDNA Synthesis System Kit (Roche
Diagnostics, cat. no. 11 117 831 001) according to
manufacturer’s instructions (Fig. 1b). The ds cDNA was
cleaned using the High Pure PCR product Purification Kit
(Roche Diagnostics, cat. no. 1 732 668 001). Circularisation
of ds cDNAwas performed using 2.5 ng/µl ds DNA and 5U
T4 DNA Ligase (Roche Diagnostics, cat. no. 1 004 786 001;
Fig. 1c). The ligation reaction was incubated overnight at
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16 °C. PCR reaction was performed using 0.75 µM of each
the sense (CYP3A_fw4 5′ agcgggaggttaaaggagat 3′) and anti-
sense primer (CYP3A_fw4 5′ gggtctgaggggttgttca 3′) and
1 µl of the ds cDNA as template (Fig. 1d). Table 1 lists the
primers used. The amplification conditions were 94 °C for
2 min for denaturing the template, 40 cycles of 94 °C for 30 s
for denaturing, 58 °C for 30 s for annealing and 68 °C for
8 min for elongation and 68 °C for 10 min for terminal
extension. The reaction was maintained at 8 °C until a second
PCR was performed with an inverse primer pair
(CYP3A_Ifw1 5′ cgcgtacagtatggatgtgg 3′/CYP3A_Irv1
5′ ccgaagacctctttaatatccac 3′) to amplify the ends of the
unknown CYP3A cDNA (Fig. 1e). PCR reaction (1 µl) was
used as template. The amplification conditions were the same
as mentioned above.
Sequence verification RT-PCR was performed to verify the
sequence found in the FHM cell line and in FHM liver
tissue. The primers used are listed in Table 1. For that
purpose the primer pair CYP3A_fw5 (5′ tcaggaaccatgagc
tacgac 3′)/CYP3A_rv5 (5′ tctcggggaacaacagaatc 3′) that
flanked the coding sequence (cds) of the CYP3A cDNA
and the primer pairs CYP3A_fw5 (5′ tcaggaaccatgagctac
gac 3′)/CYP3A_rv7 (5′ ggcgtccagatagtccatgt 3′) and
CYP3A_fw6 (5′ ttgctgatttccccagattc 3′)/CYP3A_rv5 (5′
tctcggggaacaacagaatc 3′) were used. Total RNA was
extracted from liver tissue using the RNeasy mini kit
(Qiagen, cat. no. 79254) after lysis and homogenisation of
the tissue by sonication. Total RNA from FHM cell line
was extracted as mentioned above. For cDNA synthesis
50 ng/μl total RNA, 0.75 μM oligo-dT primer and
Moloney murine leukaemia virus reverse transcriptase
(Promega Biosciences, Inc., Wallisellen, Switzerland) were
used. The reaction mixture was incubated for 5 min at 70 °C
and then for 1 h at 37 °C. The reaction was stopped by heating
at 95 °C for 5 min. PCR cycle conditions were 94 °C for 30 s
for denaturing the template, 40 cycles of 94 °C for 30 s for
denaturing, 59.1 °C for 30 s for annealing and 68 °C for 2 min
for elongation and 68 °C for 7 min for terminal extension.
Amplification products of the expected size were sequenced.
Genomic analysis Analysis on the genomic level of the
CYP3A was done in FHM cells using PCR. The PCR
reaction was performed using AccuPrime Taq DNA
Polymerase High Fidelity with 10× Accu Primer Buffer I
(Invitrogen, Switzerland, cat. no. 12346-086) and 0.75 µM
of each the sense (CYP3A_fw5) and the anti-sense primer
(CYP3A_rev5). The amplification conditions consisted of
initial denaturation (94 °C, 30 s), followed by 40 cycles for
amplification (94 °C for 30 s for denaturing, 56 °C for 30 s
for annealing and 12 min at 68 °C for elongation) and
terminal extension at 68 °C for 10 min. The amplification
product of about 8,300 bp was cleaned using the High Pure
PCR product Purification Kit (Roche Diagnostics, cat. no.
11 732 668 001) and sequenced.
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Fig. 1 Schematic explanation for the obtained CYP3A amplification.
a Total RNA extraction; b double strand synthesis; c circularisation of
ds cDNA by ligation; d PCR with primer pair CYP3A_fw4/
CYP3A_rv4: transcripts of the circulated ds DNA template annealed
together and served as a template for the polymerase; e amplification
of the new CYP3A isoenzyme with the IPCR primer pair
CYP3A_Ifw1/CYP3A_Irv1. CYP3A_fw4 and CYP3A_rv4 primer
are marked as black arrows; CYP3A_Ifw1 and CYP3A_Irv1 inverse
primer are marked as white arrows
Table 1 Primers used for inverse PCR and RT-PCR
Primer Sequence
CYP3A_fw4-sense 5′ agcgggaggttaaaggagat 3′
CYP3A_fw4-anti-sense 5′ gggtctgaggggttgttca 3′
CYP3A_Ifw1 5′ cgcgtacagtatggatgtgg 3′
CYP3A_Irv1 5′ ccgaagacctctttaatatccac 3′
CYP3A_fw5 5′ tcaggaaccatgagctacgac 3′
CYP3A_rv5 5′ tctcggggaacaacagaatc 3′
CYP3A_fw5 5′ tcaggaaccatgagctacgac 3′
CYP3A_rv7 5′ ggcgtccagatagtccatgt 3′
CYP3A_fw6 5′ ttgctgatttccccagattc 3′
CYP3A_rv5 5′ tctcggggaacaacagaatc 3′
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Determination of CYP3A mRNA
Determination of CYP3A mRNA: RNA isolation, reverse
transcription and qPCR Total RNA was isolated from
FHM and Huh7 cells using Trizol reagent according to
the manufacturer's instructions. RNA was reverse-
transcribed by Moloney murine leukaemia virus reverse
transcriptase (Promega Biosciences, Inc.) in the presence of
random hexamers (Roche) and deoxynucleoside triphosphate.
The reaction mixture was incubated for 5 min at 70 °C
and then for 1 h at 37 °C. The reaction was stopped by heating
at 95 °C for 5 min. qPCR was performed based on SYBR
green fluorescence (SYBR green PCR master mix; Roche).
Table 2 lists the primers used. The primers for the FHM
housekeeping gene G6PDH (glucose-6-phosphate dehydro-
genase) were 5′ GTGGCATGTGTGGTTCTGAC 3′ and 5′
TTGACCTTCTCGTCCCTAACA 3′. The primers for the
FHM CYP3A126 were 5′ AACGAATCGTAACGCAGCTC
3′ and 5′ TCTCGGGGAACAACAGAATC 3′. The primers
for the human GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) were 5′ GCTCCTCCTGTTCGACAGTCA
3′ and 5′ ACCTTCCCCATGGTGTCTGA 3′. The primers
for the human CYP3A4 were 5′ TCAATAACAGTCTTTC
CATTCCTCAT 3′ and 5′ CTTCGAGGCGACTTTCTTTCA
3′. The amplification conditions were 95 °C for 5 min for
initial denaturing, 40 cycles of 95 °C for 30 s for denaturing,
58 °C for 30 s for annealing and 72 °C for 45 s for
elongation. A melting curve was run afterwards. The
difference in the cycle threshold (∆CT) value was derived
by subtracting the CT value for G6PDH, which served as an
internal control, from the CT value for CYP3A. All reactions
were run in duplicates using a BioRad real-time PCR
machine (CFX 96 Real Time System). mRNA expression
levels of CYP3A were expressed as a several fold increase
according to the formula 2∆CT (untreated) −∆CT (treated).
Determination of basic CYP3A4 catalytic activity
Assay in 24-, 48- and 98-well plates Different numbers of
FHM cells were seeded in 24-, 48- and 96-well plates and
grown for 24 h in culture medium. After 24 h the medium
was removed, and FHM cells were incubated in phenol red
free medium containing either 50 μM BFC or 60 μM BQ
or AcN as solvent control, for the indicated time period.
BFC and BQ are metabolised by human and fish CYP3A4
to give the highly fluorescent 7-hydroxy-4(trifluoromethyl)
coumarin and the fluorescent 7-hydroxyquinoline. Both
metabolites can readily be detected spectrofluorometrically
[23, 27]. After this exposure time, the supernatant was
transferred into a black 96-well plate mixed with the stop
solution (80% AcN and 20% 0.5 M Tris base). The plate
was read on a GENios Tecan reader (Tecan, Männedorf,
Switzerland) using an excitation wavelength of 410 nm and
an emission wavelength of 530 nm. Each experiment was
repeated three times.
Determination of CYP3A catalytic activity after drug exposure
Assay in 96-well plates FHM and Huh7 (control) cells
(100,000 cells per well) were seeded in a 96-well plate and
grown overnight. The next day, cells were incubated in
phenol red free medium containing the indicated amount of
model inducer rifampicin (10, 25 and 50 μM and DMSO as
solvent control) and inhibitor diazepam (10 and 20 μM for
Huh7 cells and 0.1, 1 and 10 μM for FHM cells and
acetonitrile as solvent control), respectively, for 24 h. After
the incubation time the CYP3A assay was performed as
described above with BFC or BQ as substrate. The assay
for both pharmaceuticals was repeated three times, and the
number of replicates for each condition was 8.
Statistical analysis Data were graphically and statistically
evaluated with GraphPad Prism 4 (GraphPad Software, Inc.
San Diego, CA, USA). Data were analysed by one-way
ANOVA followed by a post test (Bonferroni's multiple
comparison test, significance limit p<0.05). An unpaired
t test with significance limit p<0.05 was performed to
analyse data of Figs. 5a and 6c because in both figures only
two groups were compared with each other.
Table 2 Primers used to perform real-time PCR
Primer Sequence
FHM-Glucose-6-phosphate dehydrogenase (G6PDH)-forward 5′ GTGGCATGTGTGGTTCTGAC3′
FHM-Glucose-6-phosphate dehydrogenase (G6PDH)-reverse 5′ TTGACCTTCTCGTCCCTAACA3′
FHM CYP3A126-forward 5′ AACGAATCGTAACGCAGCTC 3′
FHM CYP3A126-reverse 5′ TCTCGGGGAACAACAGAATC3′
Human glyceraldehyde-3-phosphate dehydrogenase GAPDH-forward 5′ GCTCCTCCTGTTCGACAGTCA 3′
Human glyceraldehyde-3-phosphate dehydrogenase GAPDH-reverse 5′ ACCTTCCCCATGGTGTCTGA 3′
Human CYP3A4-forward 5′ TCAATAACAGTCTTTCCATTCCTCAT3′
Human CYP3A4-reverse 5′ CTTCGAGGCGACTTTCTTTCA 3′
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Results
Full-length cDNA sequence of CYP3A126
RT-PCR was performed with RNA isolated from FHM cells
and universal CYP3A primers. Primers for inverse PCR
(IPCR) were designed based on the sequence of the
obtained RT-PCR amplification product. The full-length
cDNA sequence of the CYP3A isoform was obtained in
FHM cells by extended IPCR (Fig. 1) [28, 29]. Using this
extended IPCR, an amplification product of (∼1,800 bp)
was obtained and sequenced. The identified nucleotide
sequence (1,863 bp) contained an open reading frame of
1,536 bp encoding a 512 amino acid protein, which
comprised the putative heme binding domain—F G L G P
R N C I G M R E R F A Q—and the putative substrate
recognition sites (SRS) 1–6 (Fig. 2). The CYP3A cDNA
contained a 5′ flanking region of 15 bp, a 3′ flanking region
of 309 bp and a putative polyadenylation signal AATAAA
(Fig. 2).The translated nucleotide sequence (blastx)
revealed for the frame +1 a 89% identity (E value 0.0) to
a CYP3A form of Ctenopharyngodon idella (GenBank
access no. AAL16897; partial sequence), an 81% identity
(E value 0.0) to the Danio rerio CYP3A65 amino acid
sequence (GenBank accession no. AAH72702) as well as a
69% identity (E value 0.0) to both Oncorhynchus mykiss
CYP3A27 (GenBank accession no. O42563) and
CYP3A45 (GenBank accession no. AAK58569) and to
both Fundulus heteroclitus CYP3A30 (GenBank accession
no. Q9PVE8) and CYP3A56 (GenBank accession no.
Q8AXY5).
RT-PCR was performed to verify the sequence found in
the FHM cell line and in fathead minnow liver. Amplifi-
cation products of the expected size were obtained and
sequenced. The translated cds of the FHM cell line showed
a 100% identity to the translated CYP3A cds received by
extended IPCR. The translated cds of fathead minnow liver
tissue showed a 100% similarity and 99.4% identity to the
translated cds obtained by extended IPCR. In the translated
sequence of fathead minnow liver the amino acid (aa)
residue 42 is lysine (K), residue 217 is serine (S) and
residue 321 is serine (S), whereas in the translated sequence
of FHM cell line, residue 42 is aspargine (N), residue 217 is
aspargine (N) and residue 321 is tyrosine (T). A sequence
alignment reveals that several conserved residues in the
putative SRS (SRS 1, SRS 2 and SRS 4) show high identity
to the putative teleost recognition sites, which are different
from other vertebrate CYP3A isoenzymes (data not shown).
Analysis of expression levels of CYP3A126 was done in
FHM cells using PCR. An amplification product of about
8,300 bp was received and sequenced. The sequence
revealed that the CYP3A126 gene is composed of 13
exons and 12 introns (Fig. 2).
Constitutive CYP3A activity in FHM cells
Additional to the identification of CYP3A126, general
CYP3A enzyme activity of FHM cell lines was determined.
For this purpose, FHM cells were seeded in 96-well plates,
incubated overnight and then exposed to the CYP3A
substrate BCF. Potential CYP3A activity was determined
measuring the fluorescence. To control the experimental
setting, potential CYP3A activity of the human liver cell
line Huh7 was determined. The measured basal CYP3A
activity was even higher in FHM cells than in Huh7 cells
(Fig. 3a).
Dependence of CYP3A activity from cell numbers,
incubation time and substrate concentration
To validate the basal CYP3A activity, enzyme activity was
assessed with different numbers of FHM cells, with
different incubation times with BFC and with the additional
CYP3A substrate BQ and with different concentrations of
BFC. First, different numbers of FHM cells were seeded in
96- and 48-well plates. After 24 h of cultivation, CYP3A
activity assay was measured in culture plates. Figures 3b,
3c demonstrate that an increasing conversion of both
CYP3A substrates into the fluorescent metabolites was
detected with increasing numbers of cells. This clearly
confirms that the detected fluorescence is based on CYP3A
enzyme activity of the cells and not due to background
fluorescence. Second, FHM cells grown overnight in a 96-
well plate were incubated with both CYP3A substrates, and
the enzyme reaction was stopped at different time points (1,
2, 3 and 4 h for BFC; 8 and 16 h for BQ). As shown in
Figs. 3d, 3e, there was a correlation between incubation
time and amount of measured fluorescence. This confirms
that the measured fluorescence originates from cellular
enzyme activity. The incubation time with BQ was much
longer than with BFC due to the lower fluorescent signal of
BQ [30]. Third, FHM cells, grown in 96 well plates were
incubated with different concentrations of BFC (10, 20, 30,
40 and 50 μM) for 4 h. As shown in Fig. 3f, the measured
fluorescent reached a plateau with 40 and 50 μM. Based on
this result, we decided to use 50 μM BFC to perform the
enzyme assays.
Inhibition and induction of CYP3A activity
To confirm the potential functionality of CYP3A enzymes
in FHM cells, we evaluated the induction and inhibition
potential of CYP3A enzyme activity, respectively, by the
mammalian model compounds rifampicin and diazepam.
FHM cells and control human Huh7 cells were grown in
96-well plates and exposed to 10, 25 and 50 μM rifampicin—
a known human CYP3A inducer—for 24 h. After exposure
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Fig. 2 Nucleotide and deduced
amino acid sequence of the
fathead minnow CYP3A
isoenzyme. The initial ATG start
codon is marked by boldface,
and the stop codon has an
asterisk. The putative heme
binding domain, residues 440 to
455 of the amino acid sequence,
and the putative SRS 1–6 are
highlighted in grey. The
polyadenylation signal aataaa
is indicated by a double
underline. PCR priming sites
for the amplification of the
coding region are underlined.
Positions of the13 exons are
indicated by their respective
first nucleotide (number)
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the CYP3A activity assay was performed. Treatment of Huh7
cells with rifampicin resulted in an increase in enzyme activity
up to around 250% compared to solvent control cells, exposed
to 0.1% DMSO (Fig. 4a). The treatment of FHM cells with
rifampicin also resulted in a dose-dependent induction of
putative CYP3A enzyme activity up to around 150%
(Fig. 4b). When performing the activity assay with BQ
as a CYP3A substrate the same induction of CYP3A
activity in response to rifampicin in FHM cells was
found (Fig. 4c). In addition, a small but not significant
increase in CYP3A4 mRNA was observed in Huh7
(Fig. 5a), but not of CYP3A126 mRNA in FHM cells
(Fig. 5b). This lack of induction of CYP3A126 mRNA,
when there was an increase in putative CYP3A activity,
could indicate that there are more than one isoform of
CYP3A in fathead minnows.
Furthermore the inhibition of the putative CYP3A
activity was evaluated by treatment of FHM cells, grown
in 96-well plates, with the known human CYP3A inhibitor
diazepam for 24 h followed by CYP3A enzyme activity
measurement. Enzyme activity was inhibited in Huh7
cells (activity assay was performed with BFC) (Fig. 6a)
and in FHM cells, where activity assays were performed
with BFC and BQ (Fig. 6b, c) in a dose-dependent
manner. In addition to the enzyme activity, transcription
of the CYP3A126 gene was inhibited as indicated by the
reduction of CYP3A126 mRNA (Fig. 7). The reduction of
BCF activity could be the result of the observed reduction
of CYP3A mRNA levels.
Discussion
The CYP3A family is a large sub-family of CYPs found in
the liver and small intestine of mammals and fish [6, 31,
32]. CYP3A plays an important role in the metabolism of
endogenous substances and xenobiotics including pharma-
ceuticals. Furthermore, CYPs play a central role in the
assessment of potential effects of pollutants present in
aquatic environments [33]. Despite current knowledge on
CYP3As in fish [15], there is a need for further inves-
tigations because CYP3A plays a prominent role in the
metabolism of pharmaceuticals and xenobiotics. It is
important to obtain additional CYP3A sequences to better
understand the occurrence of CYPs in fish species and their
potential role in metabolism and effect of pollutants. This
holds true in particular for pharmaceuticals that were
identified as an emerging class of potential pollutants in
the last few years [34]. Their importance is reflected by the
fact that in mammals more than 50% of the pharmaceuticals
are metabolised by CYP3A isoforms. Metabolism by CYP3A
provides a broad defence against xenobiotics and their
bioaccumulation. Therefore evaluation of the role of CYP3A
in metabolism and effects of pharmaceuticals is important in
light of their occurrence in aquatic systems. They may also
serve as a putative biomarker for pharmaceuticals and other
xenobiotics in aquatic systems. In addition to the identification
of CYP3A isoforms it is also important to assess their enzyme
activity, in particular with respect to possible alterations of
enzyme activity induced by environmental pollutants.
Huh7 FHM
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Fig. 3 Basic CYP3A activity in FHM cells. a Basic CYP3A enzyme
activity in FHM cells and Huh7 cells was measured in 96 well plates.
Shown is the fluorescence in arbitrary units measured after 4-h incubation
with CYP3A substrate BFC. b and c Different numbers of FHM cells
were incubated with the CYP3A substrate BFC (b) for 4 h and with BQ
(c) for 16 h. Shown is the measured fluorescence in arbitrary units. d
and e FHM cells were incubated with CYP3A substrate BFC (d) and
with BQ (e) and enzymatic reaction stopped after different incubation
periods. f FHM cells were incubated with different concentrations of the
CYP3A substrate BFC for 4 h, followed by fluorescence measurement.
Shown are always the results of three independently performed
experiments±SD
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Multiple CYP3A genes have been identified in several
teleost species, e.g. CYP3A27 and CYP3A45 in rainbow trout
[6, 9], CYP3A38 and CYP3A40 in medaka [7, 8],
CYP3A30 and CYP3A56 in killifish [10] and CYP3A65 in
D. rerio [11], but not in fathead minnow thus far. In addition
to CYP3A, members of the cytochrome P450 superfamily
have important metabolic functions including the conversion
of C-18 androgens to C-19 estrogens. Therefore alterations
in enzymatic activity or gene transcription can have
pronounced consequences for the organism. Numerous
studies demonstrate that it is important to assess alterations
of CYP at the mRNA level and on enzyme activity after
exposure to xenobiotics in fish [35–42].
In our present study, we identified a CYP3A isoform in
fathead minnows, CYP3A126 (GenBank no. EU332792).
First we obtained the full-length sequence of CYP3A126 in
fathead minnow cells by extended IPCR. Second we
confirmed this CYP3A sequence in the liver tissue of
fathead minnows by RT-PCR. The analysis of the deduced
amino acid sequence demonstrates a high degree of identity
(up to 89%) with other teleost CYP3A isoenzymes.
Furthermore the substrate recognition sites SRS1, SRS2
and SRS4 show high identity to the putative teleost
recognition sites, which are different from other vertebrate
CYP3A isoenzymes. This supports the hypothesis that the
catalytic profile of teleost CYP3A members might differ
from that of other vertebrate species [7, 11].
Analysis of the complete sequences of several teleost
genomes indicates that fish species contain a complement
of CYP gene families similar to those found in mammals.
To date, 13 teleost CYP3A genes have been identified by
sequence homologies [15]. An analysis of 45 vertebrate
CYP3A deduced amino acid sequences suggested that
teleost, diapsid and mammalian CYP3A genes probably
have undergone independent diversification and that an
ancestral vertebrate genome contained a single CYP3A
gene [10, 31]. Whole genome duplications in teleosts have
been suggested [43], and multiple CYP3A paralogs have
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Fig. 5 Determination of CYP3A4 and CYP3A126 mRNA after
rifampicin treatment. Huh7 and FHM cells were treated with
rifampicin or solvent control (CON), followed by mRNA analysis. A
small yet not significant increase of CYP3A4 mRNA was detected in
Huh7 cells (a), but not of CYP3A126 in FHM cells (b)
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Fig. 4 Dose-dependent induction of CYP3A activity by rifampicin.
Treatment of Huh7 (a) and FHM (b) cells with different concen-
trations of rifampicin for 24 h or with solvent control (CON), followed
by incubation with BFC for 4 h. Induction of CYP3A activity was
significant at 25 μM (Huh7 p<0.05; FHM p<0.05) and at 50 μM
(Huh7 p<0.001; FHM p<0.01) compared to solvent control samples.
c Treatment of FHM cells with rifampicin for 24 h or with solvent
control (CON) followed by incubation with BQ for 8 h. Induction of
CYP3A activity was significant at 10 μM (p<0.05), 25 μM (p<0.01)
and 50 μM (p<0.001) compared to solvent control samples
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been identified in several species, including medaka,
rainbow trout and killifish [5–9, 31, 44]. Differences in
CYP catalytic activities are suggested to be determined by
amino acid composition in six substrate recognition sites
(SRS1 to SRS6) [45]. Key amino acids associated with
CYP3A substrate specificity, binding and region-specific
catalysis have been suggested by using molecular model-
ling and site-directed mutagenesis. Regions in SRS1, SRS5
and SRS6 were identified that appear to be associated with
a general conserved CYP3A function, whereas SRS2, SRS3
and SRS4 confer functional differences among different
CYP3A enzymes [10]. Alignments of medaka CYP3A38
and CYP3A40 demonstrate that 12 of 49 amino acids
differences occur in SR regions.
Additional to the identification of the CYP3A126
isoform, we used a newly established CYP3A activity
assay [23] to characterise general CYP3A enzyme activity
in fathead minnow cells. This in vitro assay allows to
determine the potential CYP3A enzyme activity. We used
BFC and BQ as substrates to investigate alterations in
CYP3A activity, similar to Thibaut et al. [22]. There is still
some debate whether BFC and BQ are selective enough as
substrates for the CYP3A enzyme to assess CYP3A
activity. Renwick et al. [46] showed that BFC metabolism
appears to be primarily catalysed by CYP1A2 and CYP3A4
in humans. Stresser et al. [30] tested several substrates for
their specificity to CYP3A and found that BFC and BQ
dealkylation were selective to human CYP3A with little
contribution of CYP1A2. In a previous work with mam-
malian cells, it was already shown that BFC is a good
substrate for an initial screen for CYP3A inhibition [26].
BFC was also used as a substrate to investigate CYP3A
activity [27]. Therefore we are convinced that BFC and BQ
are a good choice to investigate CYP3A activity, and
therefore we used these substrates in the present work.
We have shown that FHM cells bear a putative
constitutive CYP3A activity. The enzyme activity was
dependent on cell number, and product formation was
increased with incubation time. This demonstrates the
potential functionality of the CYP3A enzyme(s) in FHM
cells. Furthermore, we treated FHM cells with known
CYP3A inducer rifampicin and inhibitor diazepam. Similar
to Huh7, a dose-dependent induction of potential CYP3A
enzyme activity up to 150% was noted. However, the
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Fig. 7 Determination of CYP3A126 mRNA after diazepam treat-
ment. FHM cells were treated with diazepam or solvent control (CON)
followed by mRNA analysis. Significant decrease of CYP3A126
mRNA level in FHM cells compared to solvent control samples after
exposure to 10 μM diazepam for 24 h (p<0.05)
CON 10 µM 20 µM
0
25
50
75
100
125
*
*
Huh7 - CYP3A activity (BFC)a
Pe
rc
en
t
CON 0.1 µM 1 µM 10 µM
0
25
50
75
100
125
FHM-CYP3A activity (BFC)
*
b
Pe
rc
en
t
CON 10 µM
0
25
50
75
100
*
FHM - CYP3A activity (BQ)c
Pe
rc
en
t
Fig. 6 Inhibition of CYP3A activity by diazepam. a Huh7 cells
treated with 10 and 20 μM diazepam for 24 h or solvent control
(CON) showed a significant inhibition of CYP3A activity (10 μM p<
0.05 and for 20 μM p<0.01) compared to solvent control samples. b
and c Treatment of FHM cells with different concentrations of
diazepam for 24 h or solvent control (CON) followed by the
investigation of CYP3A activity with BFC (b) and BQ (c). Diazepam
(10 μM) for 24 h leads to significant inhibition of CYP3A enzyme
activity compared to solvent control samples by about 50% (p<0.001
for BFC and p<0.05 for BQ)
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induction was weaker than in Huh7 cells.We also investigated
whether the changes in enzyme activity are reflected on the
mRNA level of CYP3A126. On the mRNA level little
induction of CYP3A4 mRNA was observed in Huh7, but
none in CYP3A126 mRNA in FHM cells. The discrepancy
between CYP3A enzyme activity and CYP3A126 mRNA
expression in FHM cells suggests an additional, not yet
characterised mechanism in the regulation of CYP3A enzyme
activity or the presence of another, not yet identified CYP3A
isoform in fathead minnow. Therefore further studies are
required to analyse the complexity in the regulation of the
enzyme activity of the CYP3A sub-family in this species.
The exposure of FHM cells with CYP3A inhibitor
diazepam inhibited the CYP3A activity in a dose-dependent
manner down to 50%. Inhibition is stronger than in Huh7
cells. In addition to CYP3A enzyme activity, the transcription
of the CYP3A126 gene was decreased. This suggests
that diazepam interacts with CYP3A126 gene expression.
Hypothetically diazepam may affect the binding and/or
transcriptional activation of the PXR/RXR dimer at the
response element in the CYP3A promoter. However, the goal
of our present work was to show that a basal CYP3A activity,
which is important for the detoxification in the liver, is present
in fathead minnow and that the enzyme activity can be altered
by xenobiotics. This finding is important with regard to the
fact that aquatic organisms are constantly exposed to
pharmaceuticals and chemicals in contaminated environ-
ments. Therefore xenobiotics that decrease the enzyme
activity of CYP3A can have pronounced consequences for
the aquatic organisms due to disturbed detoxification in the
liver. Pharmaceuticals such as anti-depressive drugs have also
been detected in carp to inhibit CYP3A activity in vitro [22].
On the other hand, xenobiotics that increase the CYP3A
enzyme activity may also lead to alteration of hepatic
xenobiotic metabolism, as shown in carp for fenofibrate [22].
In summary, we identified a CYP3A isoform—
CYP3A126—in FHM cells and in fathead minnow liver
tissue. In addition, we identified a basal putative CYP3A
enzyme activity in fathead minnow cells, which can be
altered by pharmaceuticals. We provide indications that
CYP3A126 could at least partially be responsible for the
detected CYP3A activity. But we cannot exclude that there
exist other CYP3A isoforms in fathead minnow that contrib-
ute to the CYP3A activity. Furthermore we have shown that
the FHM cell line has the potential to serve as a screening tool
for the assessment of xenobiotic effects on CYP3A enzyme
activity and associated metabolism. Compounds that alter
CYP3A activity are interesting candidates for further mech-
anistic investigations and for studies in vivo.
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